Pre-transplant angiotensin II type 1 receptor antibodies: A risk factor for decreased kidney graft function in the early post-transplant period?

Revista de Investigacion Clinica

Volumn 66, Issue 3, 2014, Pages 218-224

  Hemández Méndez, Erick Alejandro ^a   Arreola Guerra, José Manuel ^a   Morales Buenrostro, Luis E ^a   Ramírez, Julia B ^a   Calleja, Said ^a   Castelán, Natalia ^a   Salcedo, Isaac ^a   Vilatobá, Mario ^a   Contreras, Alan G ^a   Gabilondo, Bernardo ^a   Granados, Julio ^a   Alberú, Josefina ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

AT1R antibodies; Graft function; Kidney transplant recipients

Indexed keywords

ANGIOTENSIN II TYPE 1 RECEPTOR ANTIBODY; HLA ANTIGEN; HLA DSA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECEPTOR ANTIBODY; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HAPLOTYPE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; AGE; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MULTIVARIATE ANALYSIS; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGE FACTORS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MULTIVARIATE ANALYSIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TRANSPLANT RECIPIENTS;

EID: 84908202701     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific or endothelial cells. Transpl Immunol 1997; 5: 321.
2. Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268.
3. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019.
4. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non human leukocyte antigenantibodies. Transplantation 2008; 85: 1557.
5. Rose ML. Role of MHC and non-MHC antibodies in graft rejection. Curr Opin Organ Transplant 2004; 9: 16.
6. 1 antibody-mediated rejection in C4d-positive renal allograft recipients. Nephrol Dial Transplant 2008; 23: 2393.
7. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal allograft rejection. N Engl J Med 2005; 352: 558.
8. Hunyadi L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953.
9. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205.
10. Reinsmoen NL. Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation. Hum Immunol 2013; 74: 1474.
11. Dragun D. The role of angiotensin II type 1 receptor activating antibodies in renal allograft vascular rejection. Pediatr Nephrol 2007; 22: 911.
12. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of ATI receptor blockade. J Am Coll Cardiol 2003; 42: 911.
13. Hunyadi L, Turu G. The role of the ATI angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 2004; 15: 405-08.
14. Maric C, Zheng W, Walther T. Interactions between angiotensin II and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol 2006; 103: 149-56.
15. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047.
16. Dragun D, Philippe A, Catar R. Role of non-HLA antibodies in organ transplantation. Transplantation 2012; 17: 440.
17. Fu ML, Herlitz H, Schulze W, et al. Autoantibodies against the angiotensin receptor (ATI) in patients with hypertension. J Hypertens 2000; 18: 945.
18. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945.
19. Zhang S, Zheng R, Yang L, et al. Angiotensin type 1 receptor autoantibody from preclamptic patients induces human fetoplacental vasoconstriction. Jour Cell Phys 2012; 228: 142.
20. LaMarca B, Parrish MR, Wallace K. Agonistic autoantibodies to the angiotensine II type I receptor cause pathophysiologic characteristics of preeclamsia. Gend Med 2012; 9: 139.
21. Miller JA, Scholey JW. The impact of renin-angiotensin polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens 2004; 13: 101.
22. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473.
23. Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transpl 2013; 10: 2567.
24. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type 1 receptor antibodies. Am J Transpl 2013; 13: 2577.
25. Van Saase J, Van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995; 59: 1280.
26. Zhang G, Wang H, Wang F, et al. Gene polymorphism of the renin-angiotensin-aldosterone system and angiotensin II type 1-receptor activating antibodies in renal rejection. Tohoku J Exp Med 2007; 213: 203.
27. Dragun D, Bräsen JH, Schönemann C, et al. Patients with steroid refractory acute vascular rejection develop agonistic anti-bodies targeting angiotensin II type 1 receptor. Transplant Proc 2003; 35: 2104.
28. Kelsch R, Everding AS, Kuwertz-Bröking E, et al. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation 2011; 92: e57.
29. Dragun D. Agonistic antibody-triggered stimulation of angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant 2007; 22: 1819.
30. Slowinski T, Suker D, Schonemann C. Screening of patients on waiting list for a renal transplant for agonistic non-HLA antibodies targeting angiotensin II type 1 receptor. J Am Soc Nephrol 2006; 17: 393A.
31. Dragun D. The detection of antibodies to the angiotensin II-type 1 receptor in transplantation. Methods Mol Biol 2013; 1034: 331.
32. Yousufuddin M, Cook DJ, Starling RC, et al. Angiotensin II receptors from peritransplantation through first-year-post-trans-plantation and the risk of transplant coronary artery disease. J Am Coll Cardiol 2004; 43: 1565.
33. Ruiz-Ortega M, Lorenzo O, Rupérez M, et al. Role of renin-angiotensin system in vascular disease. Hypertension 2001; 38: 1382.
34. Dragun D, Catar R, Kusch A. Non-HLA-antibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012; 73: 1282.
35. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation 2010; 90: 113.
36. Lukitsch I, Kehr J, Chaykovska L, et al. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012; 94: 8.